Everipedia Logo
Everipedia is now IQ.wiki - Join the IQ Brainlist and our Discord for early access to editing on the new platform and to participate in the beta testing.
δ-opioid receptor

δ-opioid receptor

The δ-opioid receptor, also known as delta opioid receptor or simply delta receptor, abbreviated DOR, is an inhibitory 7-transmembrane G-protein coupled receptor coupled to the G protein Gi/G0 and has enkephalins as its endogenous ligands.[5] The regions of the brain where the δ-opioid receptor is largely expressed vary from species model to species model. In humans, the δ-opioid receptor is most heavily expressed in the basal ganglia and neocortical regions of the brain.[6]

Available structures
PDBOrtholog search:PDBe [80] RCSB [81]
AliasesOPRD1 [85], OPRD, Δ-opioid receptor, opioid receptor delta 1, DOP, DOR1, DOR
External IDsOMIM: 165195 [86] MGI: 97438 [87] HomoloGene: 20252 [88] GeneCards: OPRD1 [89]
Gene location (Human)
Chromosome 1 (human)
Chr.Chromosome 1 (human)[1]
Chromosome 1 (human)
Genomic location for OPRD1
Genomic location for OPRD1
Band1p35.3Start28,812,142 bp[1]
End28,871,267 bp[1]
RNA expression pattern
PBB GE OPRD1 207792 at fs.png
More reference expression data [90]
4985 [142]
18386 [143]
ENSG00000116329 [144]
ENSMUSG00000050511 [145]
P41143 [146]
P32300 [147]
RefSeq (mRNA)
NM_000911 [148]
NM_013622 [149]
RefSeq (protein)
NP_000902 [150]
NP_038650 [151]
Location (UCSC)Chr 1: 28.81 – 28.87 Mb [152]Chr 4: 132.11 – 132.14 Mb [153]
PubMed search[3][4]
View/Edit HumanView/Edit Mouse


The endogenous system of opioid receptors (μ MOR,κ KOR, and, δ DOR) is well known for its analgesic potential; however, the exact role of δ-opioid receptor activation in pain modulation is largely up for debate. Largely this also depends on the model at hand since receptor activity is known to change from species to species. Activation of δ receptors produces analgesia, perhaps as significant potentiators of mu-opioid agonists. However, it seems like delta agonism provides heavy potentiation to any MOR agonism. Therefore, even selective mu agonists can cause analgesia under the right conditions, whereas others can cause none whatsoever.[7][8] It is also suggested however that the pain modulated by the mu-opioid receptor and that modulated by the δ-opioid receptor are distinct types, with the assertion that DOR modulates the nociception of chronic pain, while MOR modulates acute pain.[9]

Evidence for whether δ agonists produce respiratory depression is mixed; high doses of the δ agonist peptide DPDPE produced respiratory depression in sheep,[10] but in tests on mice the non-peptide δ agonist SNC-80 produced respiratory depression only at the very high dose of 40 mg/kg.[11] In contrast both the peptide δ agonist Deltorphin II and the non-peptide δ agonist (+)-BW373U86 actually stimulated respiratory function and blocked the respiratory depressant effect of the potent μ-opioid agonist alfentanil, without affecting pain relief.[12] It thus seems likely that while δ opioid agonists can produce respiratory depression at very high doses, at lower doses they have the opposite effect, a fact that may make mixed μ/δ agonists such as DPI-3290 potentially very useful drugs that might be much safer than the μ agonists currently used for pain relief. Many δ agonists may also cause seizures at high doses, although not all δ agonists produce this effect.[13]

Of additional interest is the potential for δ agonists to be developed for use as a novel class of antidepressant drugs, following robust evidence of both antidepressant effects[14] and also upregulation of BDNF production in the brain in animal models of depression.[15] These antidepressant effects have been linked to endogenous opioid peptides acting at δ and μ opioid receptors,[16] and so can also be produced by enkephalinase inhibitors such as RB-101.[17] ] However, in human models the data for antidepressant effects remains inconclusive. In the 2008 Phase 2 clinical trial by Astra Zeneca, NCT00759395, 15 patients were treated with the selective delta agonist AZD 2327. The results showed no significant effect on mood suggesting that delta modulation might not participate in the regulation of mood in humans. However, doses were administered at low doses and the pharmacological data also remains inconclusive.[18][19] Further trials are required.

Another interesting aspect of δ-opioid receptor function is the suggestion of mu/delta opioid receptor interactions. At the extremes of this suggestion lies the possibility of a mu-delta opioid receptor oligomer. The evidence for this stems from the different binding profiles of typical mu and delta agonists such as morphine and DAMGO respectively, in cells that coexpress both receptors compared to those in cells that express them individually. In addition, work by Fan and coworkers shows the restoration of the binding profiles when distal carboxyl termini are truncated at either receptor, suggesting that the termini play a role in the oligomerization.[20] While this is exciting, rebuttal by the Javitch and coworkers suggest the idea of oligomerization may be overplayed. Relying on RET, Javitch and coworkers showed that RET signals were more characteristic of random proximity between receptors, rather than an actual bond formation between receptors, suggesting that discrepancies in binding profiles may be the result of downstream interactions, rather than novel effects due to oligomerization.[21] Nevertheless, coexpression of receptors remains unique and potentially useful in the treatment of mood disorders and pain.

Recent work indicates that exogenous ligands that activate the δ receptors mimic the phenomenon known as ischemic preconditioning.[22] Experimentally, if short periods of transient ischemia are induced the downstream tissues are robustly protected if longer-duration interruption of the blood supply is then affected. Opiates and opioids with δ activity mimic this effect. In the rat model, introduction of δ active ligands results in significant cardioprotection.[23]


Until comparatively recently, there were few pharmacological tools for the study of δ receptors. As a consequence, our understanding of their function is much more limited than those of the other opioid receptors for which selective ligands have long been available.

However, there are now several selective δ opioid agonists available, including peptides such as DPDPE and deltorphin II, and non-peptide drugs such as SNC-80,[24] the more potent (+)-BW373U86,[25] a newer drug DPI-287, which does not produce the problems with convulsions seen with the earlier agents,[26] and the mixed μ/δ agonist DPI-3290, which is a much more potent analgesic than the more highly selective δ agonists.[27] Selective antagonists for the δ receptor are also available, with the best known being the opiate derivative naltrindole.[28]

[[INLINE_IMAGE|//upload.wikimedia.org/wikipedia/commons/b/b4/Delta_opioid_ligands.png|undefined|Delta opioid ligands.png|h474|w491]]


A showing of selective delta opioid ligands. Blue represents a common phenolic moiety, yellow a basic nitrogen, and red a diethyl amide moiety which isn't set in stone, but rather a bulky region that fits into a hydrophobic pocket.

A showing of selective delta opioid ligands. Blue represents a common phenolic moiety, yellow a basic nitrogen, and red a diethyl amide moiety which isn't set in stone, but rather a bulky region that fits into a hydrophobic pocket.

  • Leu-enkephalin

  • Met-enkephalin

  • Deltorphins



  • 7-Spiroindanyloxymorphone

  • N-Phenethyl-14-ethoxymetopon

  • ADL-5859[29]

  • BU-48

  • SNC-80

  • BW373U86

  • DPI-221

  • DPI-287

  • DPI-3290

  • TAN-67

  • RWJ-394674

  • Norbuprenorphine (peripherally restricted)

  • Cannabidiol ( non-selective)[30]

  • Xorphanol

Mitragyna speciosa (kratom) indole derivatives:

  • Mitragynine

  • Mitragynine pseudoindoxyl


  • Buprenorphine

  • Naltriben

  • Naltrindole


δ−opioid receptors have been shown to interact with β2 adrenergic receptors,[31] arrestin β1[32] and GPRASP1.[33]

See also

  • K-opioid receptor

  • μ-opioid receptor


Citation Linkmay2017.archive.ensembl.orgGRCh38: Ensembl release 89: ENSG00000116329 - Ensembl, May 2017
Oct 1, 2019, 3:20 AM
Citation Linkmay2017.archive.ensembl.orgGRCm38: Ensembl release 89: ENSMUSG00000050511 - Ensembl, May 2017
Oct 1, 2019, 3:20 AM
Citation Linkwww.ncbi.nlm.nih.gov"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
Oct 1, 2019, 3:20 AM
Citation Linkwww.ncbi.nlm.nih.gov"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
Oct 1, 2019, 3:20 AM
Citation Link//www.ncbi.nlm.nih.gov/pubmed/10471416Quock RM, Burkey TH, Varga E, Hosohata Y, Hosohata K, Cowell SM, Slate CA, Ehlert FJ, Roeske WR, Yamamura HI (Sep 1999). "The delta-opioid receptor: molecular pharmacology, signal transduction, and the determination of drug efficacy". Pharmacological Reviews. 51 (3): 503–32. PMID 10471416.
Oct 1, 2019, 3:20 AM
Citation Linkopenlibrary.orgPeppin, J.F.; Raffa, R.B. (2015). "Delta Opioid Agonists: A Concise Update on Potential Therapeutic Applications". J. Clin. Pharm. Ther. (40): 155–166.
Oct 1, 2019, 3:20 AM
Citation Link//www.ncbi.nlm.nih.gov/pubmed/15567186Varga EV, Navratilova E, Stropova D, Jambrosic J, Roeske WR, Yamamura HI (Dec 2004). "Agonist-specific regulation of the delta-opioid receptor". Life Sciences. 76 (6): 599–612. doi:10.1016/j.lfs.2004.07.020. PMID 15567186.
Oct 1, 2019, 3:20 AM
Citation Linkopenlibrary.orgAlvimopan
Oct 1, 2019, 3:20 AM
Citation Link//hdl.handle.net/10261%2F62156Berrocoso, E.; Sánchez-Blázquez, P. (2009). "Opiates as Antidepressants". Curr. Pharm. Des. 15 (14): 1612–1622. doi:10.2174/138161209788168100. hdl:10261/62156.
Oct 1, 2019, 3:20 AM
Citation Link//www.ncbi.nlm.nih.gov/pubmed/9500506Clapp JF, Kett A, Olariu N, Omoniyi AT, Wu D, Kim H, Szeto HH (Feb 1998). "Cardiovascular and metabolic responses to two receptor-selective opioid agonists in pregnant sheep". American Journal of Obstetrics and Gynecology. 178 (2): 397–401. doi:10.1016/S0002-9378(98)80032-X. PMID 9500506.
Oct 1, 2019, 3:20 AM
Citation Link//www.ncbi.nlm.nih.gov/pubmed/15943758Gallantine EL, Meert TF (Jul 2005). "A comparison of the antinociceptive and adverse effects of the mu-opioid agonist morphine and the delta-opioid agonist SNC80". Basic & Clinical Pharmacology & Toxicology. 97 (1): 39–51. doi:10.1111/j.1742-7843.2005.pto_07.x. PMID 15943758.
Oct 1, 2019, 3:20 AM
Citation Link//www.ncbi.nlm.nih.gov/pubmed/9864259Su YF, McNutt RW, Chang KJ (Dec 1998). "Delta-opioid ligands reverse alfentanil-induced respiratory depression but not antinociception". The Journal of Pharmacology and Experimental Therapeutics. 287 (3): 815–23. PMID 9864259.
Oct 1, 2019, 3:20 AM
Citation Link//www.ncbi.nlm.nih.gov/pubmed/16537798Jutkiewicz EM, Baladi MG, Folk JE, Rice KC, Woods JH (Jun 2006). "The convulsive and electroencephalographic changes produced by nonpeptidic delta-opioid agonists in rats: comparison with pentylenetetrazol". The Journal of Pharmacology and Experimental Therapeutics. 317 (3): 1337–48. doi:10.1124/jpet.105.095810. PMID 16537798.
Oct 1, 2019, 3:20 AM
Citation Link//www.ncbi.nlm.nih.gov/pubmed/12396021Broom DC, Jutkiewicz EM, Rice KC, Traynor JR, Woods JH (Sep 2002). "Behavioral effects of delta-opioid receptor agonists: potential antidepressants?". Japanese Journal of Pharmacology. 90 (1): 1–6. doi:10.1254/jjp.90.1. PMID 12396021.
Oct 1, 2019, 3:20 AM
Citation Link//www.ncbi.nlm.nih.gov/pubmed/16364263Torregrossa MM, Jutkiewicz EM, Mosberg HI, Balboni G, Watson SJ, Woods JH (Jan 2006). "Peptidic delta opioid receptor agonists produce antidepressant-like effects in the forced swim test and regulate BDNF mRNA expression in rats". Brain Research. 1069 (1): 172–81. doi:10.1016/j.brainres.2005.11.005. PMC 1780167. PMID 16364263.
Oct 1, 2019, 3:20 AM
Citation Link//www.ncbi.nlm.nih.gov/pubmed/16519663Zhang H, Torregrossa MM, Jutkiewicz EM, Shi YG, Rice KC, Woods JH, Watson SJ, Ko MC (Feb 2006). "Endogenous opioids upregulate brain-derived neurotrophic factor mRNA through delta- and micro-opioid receptors independent of antidepressant-like effects". The European Journal of Neuroscience. 23 (4): 984–94. doi:10.1111/j.1460-9568.2006.04621.x. PMC 1462954. PMID 16519663.
Oct 1, 2019, 3:20 AM
Citation Link//www.ncbi.nlm.nih.gov/pubmed/16442521Jutkiewicz EM, Torregrossa MM, Sobczyk-Kojiro K, Mosberg HI, Folk JE, Rice KC, Watson SJ, Woods JH (Feb 2006). "Behavioral and neurobiological effects of the enkephalinase inhibitor RB101 relative to its antidepressant effects". European Journal of Pharmacology. 531 (1–3): 151–9. doi:10.1016/j.ejphar.2005.12.002. PMC 1828120. PMID 16442521.
Oct 1, 2019, 3:20 AM
Citation Link//www.ncbi.nlm.nih.gov/pubmed/21444630Hudzik TJ, Maciag C, Smith MA, Caccese R, Pietras MR, Bui KH, Coupal M, Adam L, Payza K, Griffin A, Smagin G, Song D, Swedberg MD, Brown W (Jul 2011). "Preclinical pharmacology of AZD2327: a highly selective agonist of the δ-opioid receptor". The Journal of Pharmacology and Experimental Therapeutics. 338 (1): 195–204. doi:10.1124/jpet.111.179432. PMID 21444630.
Oct 1, 2019, 3:20 AM
Citation Linkclinicaltrials.gov"Study of Antidepressant Efficacy of a Selective, High Affinity Enkephalinergic Agonist in Anxious Major Depressive Disorder (AMDD) - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2015-12-11.
Oct 1, 2019, 3:20 AM
Citation Link//www.ncbi.nlm.nih.gov/pubmed/16159882Fan T, Varghese G, Nguyen T, Tse R, O'Dowd BF, George SR (Nov 2005). "A role for the distal carboxyl tails in generating the novel pharmacology and G protein activation profile of mu and delta opioid receptor hetero-oligomers" (PDF). The Journal of Biological Chemistry. 280 (46): 38478–88. doi:10.1074/jbc.M505644200. PMID 16159882.
Oct 1, 2019, 3:20 AM